Keyphrases
5-year Survival
22%
Advanced Stage
11%
Carcinoembryonic Antigen
33%
Carcinoembryonic Antigen Levels
33%
Confidence Interval
11%
Cytotoxic Agents
11%
Drug Therapy
100%
Gross Total Resection
11%
Hazard Ratio
11%
Immune Checkpoint Inhibitors
22%
Lobectomy
11%
Local Progression
11%
Molecular Targets
11%
Mortality Rate
11%
Multi-institutional
100%
Multivariate Analysis
11%
Non-small Cell Lung Cancer (NSCLC)
100%
Overall Survival
22%
Overall Survival Rate
11%
Postoperative Complications
11%
Primary Lesion
11%
Prognostic Factors
100%
Prognosticator
11%
Progression-free Survival
11%
Retrospective Investigation
11%
Salvage Surgery
100%
Segmentectomy
11%
Serious Complications
11%
Tumor
11%
Tyrosine Kinase Inhibitor
11%
Tyrosine Kinase Inhibitor Therapy
22%
Wedge Resection
11%
Medicine and Dentistry
Carcinoembryonic Antigen
33%
Clinical Stage
11%
Cytotoxic Agent
11%
Drug Therapy
100%
Hazard Ratio
11%
Immune Checkpoint Inhibitor
22%
Lobectomy
11%
Mortality Rate
11%
Multivariate Analysis
11%
Non Small Cell Lung Cancer
100%
Overall Survival
44%
Postoperative Complication
11%
Prevalence
11%
Prognostic Factor
100%
Progression Free Survival
11%
Retrospective Study
100%
Segmentectomy
11%
Surgery
11%
Survival Rate
22%
Tumor Progression
11%
Tyrosine-Kinase Inhibitor
33%
Wedge Resection
11%
Pharmacology, Toxicology and Pharmaceutical Science
Carcinoembryonic Antigen
33%
Cytotoxic Agent
11%
Immune Checkpoint Inhibitor
22%
Mortality Rate
11%
Non Small Cell Lung Cancer
100%
Overall Survival
44%
Pharmacotherapy
100%
Postoperative Complication
11%
Prevalence
11%
Progression Free Survival
11%
Protein Tyrosine Kinase Inhibitor
33%
Retrospective Study
100%
Survival Rate
22%
Tumor Growth
11%